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Abstract
Introduction Available clinical data on the influence of baseline HbA1c postoperative morbidity and readmission after
laparoscopic sleeve gastrectomy is scarce. This prompted us to conduct a multicenter retrospective study evaluating
the influence of chronic hyperglycemia on postoperative course among patients undergoing laparoscopic sleeve
gastrectomy (SG). We aimed to investigate the influence of baseline HbA1c levels on postoperative outcomes in
patients after SG.
Material and Methods We conducted a multicenter retrospective cohort study of consecutive patients who underwent SG from
March 2017 to March 2018 in seven referral centers for bariatric surgery. Exclusion criteria were revision surgeries,
different bariatric interventions, SG combined with other procedures, and lack of necessary data. Patients were
divided into three groups depending on their preoperative glycated hemoglobin level (HbA1c) < 5.7%, 5.7–6.4%,
and ≥ 6.5%. Primary endpoints were influence of HbA1c on early and late postoperative morbidity, impact on
prolonged length of hospital stay (LOS), and readmission rate.
Results The HbA1c < 5.7% group comprised 842 (49%) patients, HbA1c 5.7–6.4% comprised 587 (34%), and HbA1c ≥ 6.5%
comprised 289 (17%). Overall morbidity was 6.23%; this did not differ among groups (p = 0.571). Three patients
died postoperatively. Late postoperative morbidity was comparable among groups (p = 0.312). The ratio of prolonged
LOS and readmission did not differ among groups (p = 0.363 and 0.571). ROC analysis revealed that HbA1c > 7.3%
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Conclusion Preoperative HbA1c does not affect postoperative morbidity and prolonged LOS after SG. Patients with HbA1c >
7.3% have an increased chance of hospital readmission.
Keywords Laparoscopic sleeve gastrectomy . Glycated hemoglobin . Postoperative morbidity . Postoperative mortality . Length
of hospital stay . Readmission
Introduction
It is believed that almost every surgical procedure induces a
stress response that may be responsible for morbidity and
mortality [1]. Patients with diabetes mellitus type 2 (DM2)
and chronic hyperglycemia, reflected by elevated glycated
hemoglobin level (HbA1c), may be particularly exposed to
perioperative morbidity from diabetes-related complications
[2, 3]. DM2 and increased mortality and morbidity in cardiac
surgery are connected [4, 5]. This association is less clearly
documented in other surgical fields [6–10].
HbA1c has been proposed as a reliable indicator of glyce-
mic status in the preoperative period because it is unaffected
by fasting status. Furthermore, it is less affected by stress
hyperglycemia than glycemic status [11, 12]. It has therefore
been accepted as an appropriate method for diagnosing and
monitoring DM2 [13, 14]. A meta-analysis investigating the
association between HbA1c and surgical outcomes in different
branches of surgery has shown conflicting results and did not
include bariatric surgery [15]. We found scarce clinical data
regarding the influence of baseline HbA1c on postoperative
morbidity and readmission after laparoscopic sleeve gastrec-
tomy. This prompted us to conduct this multicenter retrospec-
tive study, evaluating the influence of chronic hyperglycemia
on postoperative course among patients undergoing laparo-
scopic sleeve gastrectomy (SG). To the best of our knowledge,
this problem has not yet been investigated [16–20].
Aim of the Study
The aim of this study was to assess the influence of baseline
HbA1c levels on postoperative outcomes in patients undergo-
ing laparoscopic sleeve gastrectomy.
Material and Methods
Methods
A retrospective cohort study was used to analyze consecutive
patients who underwent surgical treatment for morbid obesity
in seven referral bariatric centers in Poland from March 2017
to March 2018. Each participating center provided specific
data, which were processed and used in the overall analysis.
The study was designed and described according to the
STROBE guidelines for observational studies [21]. The in-
cluded patients underwent laparoscopic sleeve gastrectomy.
Each patient qualified for surgical treatment in accordance
with the Polish Guidelines for Metabolic and Bariatric
Surgery [22]. Exclusion criteria were revision surgeries, dif-
ferent bariatric operations, sleeve gastrectomy combined with
other procedures, and lack of necessary data (only patients
with complete follow-up were included). All procedures were
performed laparoscopically using comparable surgical tech-
niques, and perioperative care was based on standardized pro-
tocols, which ensured reliable data comparison. HbA1c was
measured on the day of hospital admission. Patients were di-
vided into three groups depending on their preoperative
glycated hemoglobin level (HbA1c) HbA1c < 5.7%, HbA1c
5.7–6.4%, and HbA1c ≥ 6.5%. These values equate to the
American Diabetes Association definitions of normal
HbA1c, prediabetes, and diabetes mellitus [13]. Baseline char-
acteristics were sex, age, bodymass index (BMI), and relevant
comorbidities.
Primary endpoints included the influence of the HbA1c
level on early postoperative morbidity (30 days) and late post-
operative morbidity (12 months excluding the first 30 days),
including mortality. influence on the rate of prolonged length
of hospital stay (prolonged LOS), and readmission rate.
Secondary endpoints were to determine HbA1c cut-off points
and when the odds ratio (OR) of primary endpoints signifi-
cantly rose.
Definitions
Postoperative morbidity was defined as any deviation from
the standard postoperative course that required additional
measures to correct. LOS was defined as the period from
surgery to discharge. Prolonged LOS was defined as > 4 days
because the hospitalization for surgical bariatric treatment was
planned for a maximum of 4 days. Readmissions were ana-
lyzed only if they occurred in the indexed hospitals.
Ethics
All procedures performed in the study involving human
participants were in accordance with the ethical stan-
dards of the institutional and national research commit-
tee and with the 1964 Helsinki declaration and its later
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amendments or comparable ethical standards. Formal
consent was not required for this study.
Statistical Analysis
Calculations were performed using Statistica 13.5 soft-
ware (StatSoft®, Tulsa, OK, USA). Continuous values
were presented as means with standard deviations or
medians with interquartile ranges when appropriate.
Quantitative variables were compared using the
Kruskal-Wallis ANOVA with post hoc multiple compar-
isons of ranges. Qualitative variables were compared
using the Pearson χ-square with or without Yates’ cor-
rection. Receiver operating characteristic (ROC) curves
were used to set HbA1c cutoffs; then, univariate logistic
regression models were built. Significant univariate lo-
gistic regression was adjusted for relevant intergroup
baseline differences in multivariate analyses to calculate
the OR with 95% confidence interval (CI). P values ≤
0.05 were considered statistically significant.
Material
The study group comprised 1718 patients from seven bariatric




Group characteristics depending on the level of glycated he-
moglobin are presented in Table 2. Median HbA1c was 5.7%
(5.3%–6.1%). Sex distribution significantly differed between
HbA1C groups, with an increasing prevalence of male patients
from the HbA1C < 5.7% to HbA1C ≥ 6.5% groups (29%, 35%,
and 47%; p < 0.001). Multiple range comparisons in Kruskal-
Wallis ANOVA showed a significant increase in age from the
HbA1C < 5.7% to HbA1C ≥ 6.5% groups (p < 0.001). This was
also the same for patients’ preoperative BMI.
Primary Outcomes
Table 3 presents postoperative outcomes of the whole study
population.
The overall morbidity rate was 6.23% (107 patients);
this did not differ among groups (p = 0.571). Neither the
early nor late postoperative morbidity rate differed
among groups (68 patients, p = 0.445 and 39 patients,
p = 0.312 respectively). Details of clinical outcomes in
each group are presented in Table 4. There were three
early postoperative deaths (0.17%); these were due to
urosepsis (HbA1c = 6.7%), gastric leak (HbA1c = 7.8%),
and gastric leak and pancreatitis (HbA1c = 5.2%). There
were no deaths in the late postoperative period. The
ratio of prolonged LOS did not differ among groups
(p = 0.363). The readmission rate did not differ signifi-
cantly among groups (p = 0.571). Patients with no pre-
operative diagnosis of DM2 who were in the HbA1c ≥
6.5% group did not have increased ORs for early post-
operative (OR 0.62, 95%CI 0.22–1.73, p = 0.361) or late
postoperative complications (1.87, 95%CI 0.77–4.53,
p = 0.167). Those patients also did not have increased
ORs for prolonged LOS (OR 1.42, 95%CI 0.65–3.08,
p = 0.379) or hospital readmission (OR 0.38 (0.05–
2.85, p = 0.349).
Table 1 General characteristics
N (%) 1718 (100%)
Males/females, n (%) 585/1133 (34%/66%)
Median age, years (IQR) 41 (35–51)
Median BMI, kg/m2 (IQR) 44.1 (40.3–48.77)
Arterial hypertension, n (%) 787 (45.8%)
Obstructive sleep apnea, n (%) 218 (12.69%)
Median operative time, min (IQR) 70 (55.5–90)
Table 2 Group characteristics
HbA1c < 5.7% HbA1c 5.7–6.4% HbA1c ≥ 6.5% p value
N (% total) 842 (49%) 587 (34%) 289 (17%) N/a
Diabetes mellitus type 2, n (%) 77 (8.95%) 132 (22.39%) 134 (46.37%) < 0.001
No diagnosis of diabetes mellitus type 2, n (%) 765 (91.05%) 455 (77.61%) 155 (53.63%)
Males/females, n (%) 243/599 (29%/71%) 205/382 (35%/65%) 137/152 (47%/53%) < 0.001
Median age, years (IQR) 38 (32–47) 43 (35–53) 48 (40–57) < 0.001
Median BMI, kg/m2 (IQR) 43 (40–48) 44 (40–49) 47 (42–52) < 0.001
Arterial hypertension, n (%) 287 (34%) 309 (53%) 191 (66%) < 0.001
Obstructive sleep apnea, n (%) 66 (8%) 89 (15%) 63 (22%) < 0.001
OBES SURG (2019) 29:2957–2962 2959
Secondary Outcomes
Surprisingly, analyses of the ROC curves did not reveal any
HbA1c cutoff point that would significantly increase ORs for
primary endpoints. The only significant findingwas that patients
in the HbA1c > 7.3% group had a higher likelihood of hospital
readmission, as shown in Table 5. In multivariate logistic regres-
sion analysis, HbA1c remained the only significant factor for
readmissions (OR 4.59, 95%CI 1.61–13.06, p = 0.004).
Discussion
This is the first study to investigate the influence of preoper-
ative HbA1c levels on postoperative outcomes after laparo-
scopic sleeve gastrectomy. Our literature search revealed that
the available information in the literature regarding this sub-
ject is limited. Previous studies predominantly analyzed pa-
tients after gastric bypass surgery. No studies investigating
laparoscopic sleeve gastrectomy were found. Our study
showed that baseline HbA1c levels did not increase the likeli-
hood of early and late postoperative morbidity or prolonged
LOS. Further analysis revealed that patients with baseline
HbA1c > 7.3% had increased OR for hospital readmission.
The influence of baseline preoperative glycated hemoglobin
HbA1c levels on surgical morbidity has not been clearly deter-
mined, as presented in a systematic review byRollins et al. [15].
HbA1c was validated as an appropriate method for diagnosing
DM2 by diabetes specialist consensus [3, 13]. However, in the
Polish Guidelines on the management of diabetic patients,
HbA1c is not recommended for diagnosing DM2 [23]. DM2
is diagnosed based on the fasting blood glucose level and/or
fasting oral glucose tolerance test. In our study, 155 patients
were in the HbA1c ≥ 6.5% group. Although they should have
been diagnosed and treated for DM2, the routine preoperative
assessment did not diagnose them with DM2. Despite this, the
early and late postoperative morbidity did not increase.
The available literature analyzed the influence of HbA1c on
postoperative outcomes after laparoscopic Roux-en-Y gastric
bypass (LRYGB). Perna et al. published a study comprising
468 patients who underwent gastric bypass for morbid obesity
[18]. They divided patients into three groups depending on
their HbA1c level HbA1c < 6.5%, 6.5–7.9%, and ≥ 8.0%.
They found no difference in overall complications or mortal-
ity. Ayear later, Rawlins et al. published a study analyzing the
results of surgical treatment of 342 morbidly obese patients
with DM2 who underwent LRYGB [19]. They found no sig-
nificant increase in 1-year postoperative morbidity in patients
with > 7%HbA1c [19]. Cruijsen et al. designed a single-center
observational study involving 85 DM2 patients with a BMI ≥
35 kg/m2 who were scheduled for LRYGB [17]. Preoperative
glycemic control was comparable in patients with and without
surgical complications because HbA1c levels were compara-
ble in both groups [17]. In our study, patients’ early postoper-
ative morbidity was comparable among groups. Similar find-
ings were also true for late postoperative morbidity. Neither
did we find differences in the HbA1c levels in the case of
patients with and without prolonged LOS. Chuah et al. de-
signed GLUCOSURG-pre RCT in which he divided DM2
patients to directly undergo LRYGB or to receive intensive
preoperative DM2 treatment to preoperatively normalize
HbA1c levels [16]. Shockingly, neither LOS, nor 30-day peri-
operative complications differed among groups.
Our study improves the current knowledge of the influence
of preoperative glucose metabolic state on postoperative SG
outcomes. The HbA1c level represents median blood glucose
concentrations in the past 4 months, which should be the period
Table 3 Postoperative outcomes
Median LOS, days (IQR) 3 (3–4)
Prolonged LOS, n (%) 94 (5.47%)
Overall morbidity, n (%) 107 (6.23%)
Early postoperative morbidity, n (%) 68 (3.96%)
Early postoperative mortality, n (%) 3 (0.17%)
Late postoperative morbidity (excluding 1st postoperative
month), n (%)
39 (2.27%)
Readmissions, n (%) 27 (1.57%)
Table 4 Clinical outcomes
HbA1c < 5.7% HbA1c 5.7–6.4% HbA1c ≥ 6.5% p value
N (% total) 842 (49%) 587 (34%) 289 (17%) N/a
Overall morbidity, n (%) 47 (5.58%) 39 (6.64%) 21 (7.27%) 0.571
Early postoperative morbidity, n (%) 29 (3.44%) 28 (4.77%) 11 (3.81%) 0.445
Early postoperative mortality, n (%) 1 (0.12%) 0 2 (0.69%) 0.124
Late postoperative morbidity, n (%) 18 (2.14%) 11 (1.87%) 10 (3.46%) 0.312
Prolonged LOS, n (%) 40 (4.75%) 31 (5.28%) 21 (7.28%) 0.363
Prolonged LOS > 3 days 281 (33.37%) 150 (25.56%) 103 (35.64%) 0.017
Prolonged LOS > 5 days 13 (1.54%) 18 (3.07%) 10 (3.46%) 0.196
Readmissions, n (%) 47 (5.58%) 37 (6.30%) 21 (7.28%) 0.571
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of intensive preoperative preparations. There were patients
whose fasting glucose level was either normal or who would
be diagnosed with glucose intolerance; however, according to
HbA1c, they would have been diagnosed with DM2.
Fortunately, this did not translate into postoperative morbidity
and mortality. Patients with high preoperative HbA1c levels
who underwent SG were at increased risk of hospital readmis-
sion. Further studies such as RCT similar to GLUCOSURG
that focuses on patients with DM2 undergoing SG are required
to extensively assess this subject. Additional data on the influ-
ence of gut hormone changes, stress response, variability of
glucose concentrations, and preoperative glucose metabolic
state would be useful to build a comprehensive answer to the
question of the significance of preoperative glycemic control
improvement for postoperative safety [12, 25, 26]. [24]
Limitations
The results of our study are limited by several aspects typical
for observational multicenter reports. This was a non-
randomized analysis and our groups were demographically
heterogeneous and differed in preoperative factors.
Furthermore, as the data were collected separately from seven
bariatric centers using different electronic systems, some nec-
essary information were lacking in our initial population, so
we had to exclude some patients. We did not record postoper-
ative events that occurred outside the indexed hospitals.
Follow-up was complete in 86% of patients. The end of the
study was in March 2018 and follow-up of 14% of patients
was limited to 9 months. We did not analyze perioperative
care protocols or operative techniques in each hospital.
Another limitation is the fact that we have not investigated
diabetes remission and bariatric effects 1 year after surgery.
Conclusions
HbA1c ≥ 6.5% is common among patients undergoing SG
(17%). Preoperative HbA1c level is not associated with postop-
erative outcomes after laparoscopic sleeve gastrectomy, includ-
ing postoperative morbidity and prolonged LOS. Patients with
HbA1c > 7.3% have a higher risk of hospital readmission.
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